
## Sadahiko Nishizawa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2103688/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Physiological 18F-FDG uptake in the ovaries and uterus of healthy female volunteers. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 549-556.	6.4	109
2	A Multicenter Validation of Regional Cerebral Blood Flow Quantitation Using [1231]Iodoamphetamine and Single Photon Emission Computed Tomography. Journal of Cerebral Blood Flow and Metabolism, 1996, 16, 781-793.	4.3	95
3	The current status of an FDG-PET cancer screening program in Japan, based on a 4-year (2006–2009) nationwide survey. Annals of Nuclear Medicine, 2013, 27, 46-57.	2.2	66
4	Performance profile of FDG-PET and PET/CT for cancer screening on the basis of a Japanese Nationwide Survey. Annals of Nuclear Medicine, 2007, 21, 481-498.	2.2	58
5	Incidence and characteristics of uterine leiomyomas with FDG uptake. Annals of Nuclear Medicine, 2008, 22, 803-810.	2.2	52
6	High incidence of thyroid cancer in focal thyroid incidentaloma detected by 18F-fluorodexyglucose positron emission tomography in relatively young healthy subjects: results of 3-year follow-up. Endocrine Journal, 2010, 57, 395-401.	1.6	52
7	Prospective Evaluation of Whole-Body Cancer Screening With Multiple Modalities Including [ <sup>18</sup> F]Fluorodeoxyglucose Positron Emission Tomography in a Healthy Population: A Preliminary Report. Journal of Clinical Oncology, 2009, 27, 1767-1773.	1.6	47
8	Radiation exposure and risk–benefit analysis in cancer screening using FDG-PET: results of a Japanese nationwide survey. Annals of Nuclear Medicine, 2011, 25, 657-666.	2.2	33
9	Uncoupling of Oxygen and Glucose Metabolism in Persistent Crossed Cerebellar Diaschisis. Stroke, 1999, 30, 1424-1428.	2.0	27
10	Analysis of various malignant neoplasms detected by FDG-PET cancer screening program: based on a Japanese Nationwide Survey. Annals of Nuclear Medicine, 2011, 25, 45-54.	2.2	24
11	Regional Cerebral Blood Flow and Oxygen Metabolism in Normal Pressure Hydrocephalus after Subarachnoid Hemorrhage. Neurologia Medico-Chirurgica, 1989, 29, 382-388.	2.2	22
12	Presurgical identification of epileptic foci with iodine-123 iomazenil SPET: Comparison with brain perfusion SPET and FDG PET. European Journal of Nuclear Medicine and Molecular Imaging, 1997, 24, 27-34.	2.1	22
13	Physiological FDG uptake in the ovaries after hysterectomy. Annals of Nuclear Medicine, 2007, 21, 345-348.	2.2	13
14	Assessment of cerebral hemodynamics before and after revascularization in patients with occlusive cerebrovascular disease by means of quantitative IMP-SPECT with double-injection protocol. Annals of Nuclear Medicine, 2001, 15, 209-15.	2.2	12
15	Validation of the dual-table autoradiographic method to quantify two sequential rCBFs in a single SPET session with N -isopropyl-[ 123 l] p -iodoamphetamine. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 943-950.	6.4	12
16	Clinical application of62Zn/62Cu positron generator: Perfusion and plasma pool images in normal subjects. Annals of Nuclear Medicine, 1995, 9, 81-87.	2.2	11
17	A new method to estimate rCBF using IMP and SPECT without any blood sampling. Annals of Nuclear Medicine, 2000, 14, 433-440.	2.2	10
18	Double-injection FDG method to measure cerebral glucose metabolism twice in a single procedure. Annals of Nuclear Medicine, 2001, 15, 203-207.	2.2	8

#	Article	IF	CITATIONS
19	Glucose Consumption and Rate Constants for <sup>18</sup> F-fluorodeoxyglucose in Human Gliomas. Neurologia Medico-Chirurgica, 1990, 30, 377-381.	2.2	7
20	Prospective Employer-Initiated Whole-Body Cancer Screening—Costs and Outcomes of a Cancer Screening Program in Japan. Journal of the American College of Radiology, 2021, 18, 140-147.	1.8	3
21	Functional magnetic resonance imaging of human cognitive processes. Japanese Psychological Research, 2000, 42, 26-35.	1.1	2
22	Ten-year prospective evaluation of whole-body cancer screening with multiple modalities including [18F]fluorodeoxyglucose positron emission tomography in a healthy population. Annals of Nuclear Medicine, 2020, 34, 358-368.	2.2	2